Advertisement

Management of Hospitalized Kidney Transplant Recipients for Hospitalists and Internists

  • Sam Kant
    Affiliations
    Division of Nephrology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Md
    Search for articles by this author
  • Sandeep Soman
    Affiliations
    Division of Nephrology and Hypertension, Henry Ford Hospital, Detroit, Mich
    Search for articles by this author
  • Michael J. Choi
    Affiliations
    Division of Nephrology and Hypertension, MedStar Georgetown University Hospital, Washington, DC
    Search for articles by this author
  • Author Footnotes
    1 BGJ and DBA contributed equally to this work.
    Bernard G. Jaar
    Correspondence
    Requests for reprints should be addressed to Bernard G. Jaar, MD, MPH, Johns Hopkins Medical Institutions, 2024 E Monument St, Room 318B, Baltimore, MD 21205.
    Footnotes
    1 BGJ and DBA contributed equally to this work.
    Affiliations
    Division of Nephrology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Md

    Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Md

    Welch Center for Prevention, Epidemiology, and Clinical Research, Baltimore, Md

    Nephrology Center of Maryland, Baltimore
    Search for articles by this author
  • Author Footnotes
    1 BGJ and DBA contributed equally to this work.
    Deborah B. Adey
    Footnotes
    1 BGJ and DBA contributed equally to this work.
    Affiliations
    Division of Nephrology, Department of Medicine, University of California, San Francisco
    Search for articles by this author
  • on behalf of theNational Kidney Foundation Education Committee
  • Author Footnotes
    1 BGJ and DBA contributed equally to this work.

      Abstract

      The number of kidney transplant recipients has grown incrementally over the years. These patients have a high comorbidity index and require special attention to immunosuppression management. In addition, this population has an increased risk for cardiovascular events, electrolyte abnormalities, allograft dysfunction, and infectious complications. It is vital for hospitalists and internists to understand the risks and nuances in the care of this increasingly prevalent, but also high-risk, population.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. Hart A, Lentine KL, Smith JM, et al. OPTN/SRTR 2019 annual data report: kidney. Am J Transplant. 2021;21(suppl 2):21-137. Available at:https://onlinelibrary.wiley.com/doi/abs/10.1111/ajt.16502. Accessed 12 June 2021.

        • Wu C
        • Evans I
        • Joseph R
        • et al.
        Comorbid conditions in kidney transplantation: Association with graft and patient survival.
        J Am Soc Nephrol. 2005; 16: 3437-3444
        • Brennan DC
        • Daller JA
        • Lake KD
        • Cibrik D
        • Del Castillo D
        • Thymoglobulin Induction Study Group
        Rabbit antithymocyte globulin versus basiliximab in renal transplantation.
        N Engl J Med. 2006; 355 (Available at) (Accessed 12th June 2021): 1967-1977
        • Kasiske BL
        • Zeier MG
        • Chapman JR
        • et al.
        KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary.
        Kidney Int. 2010; 77 (Available at) (Accessed 12th June 2021): 299-311
        • Webster AC
        • Woodroffe RC
        • Taylor RS
        • Chapman JR
        • Craig JC
        Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: Meta-analysis and meta-regression of randomised trial data.
        BMJ. 2005; 331 (Available at) (Accessed 12th June 2021): 810-814
        • Ekberg H
        • Tedesco-Silva H
        • Demirbas A
        • et al.
        Reduced exposure to calcineurin inhibitors in renal transplantation.
        N Engl J Med. 2007; 357 (Available at) (Accessed 12th June 2021): 2562-2575
      2. Envarsus. Envarsus XR prescribing information 6/2015. Available at:http://www/envarsusxr.com/files/1814/4899/3398/EnvarsusXR_PI_8_4_15.pdf. Accessed 12 June 2021.

        • Izzedine H
        • Brocheriou I
        • Frances C
        Post-transplantation proteinuria and sirolimus.
        N Engl J Med. 2005; 353 (Available at:) (Accessed 12th June 2021): 2088-2089
        • Wagner M
        • Earley AK
        • Webster AC
        • Schmid CH
        • Balk EM
        • Uhlig K
        Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipients.
        Cochrane Database Syst Rev. 2015; (Available at:) (Accessed 12th June 2021)CD007746
      3. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group.
        Transplantation. 1996; 61: 1029-1037
        • Vincenti F
        • Rostaing L
        • Grinyo J
        • et al.
        Belatacept and long-term outcomes in kidney transplantation.
        N Engl J Med. 2016; 374 (Available at:) (Accessed 12 June 2021): 333-343
        • Sam T
        • Gabardi S
        • Tichy EM
        Risk evaluation and mitigation strategies: a focus on belatacept.
        Prog Transplant. 2013; 23 (Available at:) (Accessed 12 June 2021): 64-70
        • Dharnidharka VR
        • Schnitzler MA
        • Chen J
        • et al.
        Differential risks for adverse outcomes 3 years after kidney transplantation based on initial immunosuppression regimen: a national study.
        Transplant Int. 2016; 29 (Available at:) (Accessed 12 June 2021): 1226-1236
        • Bae S
        • Garonzik Wang JM
        • Massie AB
        • et al.
        Early steroid withdrawal in deceased-donor kidney transplant recipients with delayed graft function.
        J Am Soc Nephrol. 2020; 31: 175-185
        • Haller MC
        • Royuela A
        • Nagler EV
        • Pascual J
        • Webster AC
        Steroid avoidance or withdrawal for kidney transplant recipients.
        Cochrane Database Syst Rev. 2016; 2016 (Available at:) (Accessed 12th June 2021)CD005632
        • Jiang Y
        • Villeneuve PJ
        • Schaubel D
        • Mao Y
        • Rao P
        • Morrison H
        Long-term follow-up of kidney transplant recipients: comparison of hospitalization rates to the general population.
        Transplant Res. 2013; 2: 15
        • Weeda ER
        • Su Z
        • Taber DJ
        • et al.
        Hospital admissions and emergency department visits among kidney transplant recipients.
        Clin Transplant. 2019; 33 (Available at:) (Accessed 12 June 2021): e13522
        • Aakhus S
        • Dahl K
        • Widerøe TE
        Cardiovascular morbidity and risk factors in renal transplant patients.
        Nephrol Dial Transplant. 1999; 14 (Available at:) (Accessed 12 June 2021): 648-654
        • Silkensen JR
        Long-term complications in renal transplantation.
        J Am Soc Nephrol. 2000; 11: 582-588
        • Kasiske BL
        • Maclean JR
        • Snyder JJ
        Acute myocardial infarction and kidney transplantation.
        J Am Soc Nephrol. 2006; 17: 900-907
        • Lentine KL
        • Brennan DC
        • Schnitzler MA
        Incidence and predictors of myocardial infarction after kidney transplantation.
        J Am Soc Nephrol. 2005; 16: 496-506
        • Herzog CA
        • Ma JZ
        • Collins AJ
        Poor long-term survival after acute myocardial infarction among patients on long-term dialysis.
        N Engl J Med. 1998; 339 (Available at:) (Accessed 12 June 2021): 799-805
        • Gupta T
        • Kolte D
        • Khera S
        • et al.
        Management and outcomes of ST-segment elevation myocardial infarction in US renal transplant recipients.
        JAMA Cardiol. 2017; 2 (Available at:) (Accessed 12 June 2021): 250-258
        • Lentine KL
        • Rocca Rey LA
        • Kolli S
        • et al.
        Variations in the risk for cerebrovascular events after kidney transplant compared with experience on the waiting list and after graft failure.
        Clin J Am Soc Nephrol. 2008; 3 (Available at:) (Accessed 12 June 2021): 1090-1101
        • De La Mata N
        • Masson P
        • Al-Shahi Salman R
        • Kelly P
        • Webster A
        Stroke mortality in kidney transplant recipients: a retrospective population-based cohort study using data linkage.
        Transplantation. 2018; 102 (Available at:) (Accessed 12 June 2021): S423-S424
        • Severova-Andreevska G
        • Danilovska I
        • Sikole A
        • Popov Z
        • Ivanovski N
        Hypertension after kidney transplantation: clinical significance and therapeutical aspects.
        Open Access Maced J Med Sci. 2019; 7: 1241-1245
        • Voiculescu A
        • Schmitz M
        • Hollenbeck M
        • et al.
        Management of arterial stenosis affecting kidney graft perfusion: a single-centre study in 53 patients.
        Am J Transplant. 2005; 5 (Available at:) (Accessed 12 June 2021): 1731-1738
        • Snyder JJ
        • Israni AK
        • Peng Y
        • Zhang L
        • Simon TA
        • Kasiske BL
        Rates of first infection following kidney transplant in the United States.
        Kidney Int. 2009; 75 (Available at:) (Accessed 12 June 2021): 317-326
        • Dharnidharka VR
        • Agodoa LY
        • Abbott KC
        Risk factors for hospitalization for bacterial or viral infection in renal transplant recipients—an analysis of USRDS data.
        Am J Transplant. 2007; 7 (Available at:) (Accessed 12 June 2021): 653-661
        • Fishman JA
        Infection in solid-organ transplant recipients.
        N Engl J Med. 2007; 357 (Accessed 12 June 2021): 2601-2614https://doi.org/10.1056/NEJMra064928
        • Patel R
        • Paya CV
        Infection in solid-organ transplant recipients.
        Clin Microbiol Rev. 1997; 10: 86-124
        • Wyner LM
        The evaluation and management of urinary tract infections in recipients of solid-organ transplants.
        Semin Urol. 1994; 12: 134-139
        • Li G
        • Trac J
        • Husain S
        • Famure O
        • Li Y
        • Kim S
        Incidence, risk factors, and outcomes of Clostridium difficile infections in kidney transplant recipients.
        Transplantation. 2018; 102 (Available at:) (Accessed 12 June 2021): 1576-1581
        • Brennan DC
        Cytomegalovirus in renal transplantation.
        J Am Soc Nephrol. 2001; 12: 848-855
        • Hirsch HH
        • Randhawa PS
        BK polyomavirus in solid organ transplantation—guidelines from the american society of transplantation infectious diseases community of practice.
        Clin Transplant. 2019; 33 (Available at:) (Accessed 12 June 2021): e13528
        • Kant S
        • Menez SP
        • Hanouneh M
        • et al.
        The COVID-19 nephrology compendium: AKI, CKD, ESKD and transplantation.
        BMC Nephrol. 2020; 21: 449
        • Hagerty JA
        • Ortiz J
        • Reich D
        • Manzarbeitia C
        Fungal infections in solid organ transplant patients.
        Surg Infect (Larchmt). 2003; 4: 263-271
        • Khoury JA
        • Brennan DC
        Infectious complications in kidney transplant recipients: review of the literature.
        Saudi J Kidney Dis Transpl. 2005; 16: 453-497
        • Mehrotra A
        • Rose C
        • Pannu N
        • Gill J
        • Tonelli M
        • Gill JS
        Incidence and consequences of acute kidney injury in kidney transplant recipients.
        Am J Kidney Dis. 2012; 59 (Available at:) (Accessed 12 June 2021): 558-565
        • Ardalan MR
        • Tarzamni MK
        Renal allograft hemodynamic and diameter changes after living donor transplantation.
        Transplant Proc. 2006; 38 (Available at:) (Accessed 12 June 2021): 388-389
        • Liptak P
        • Ivanyi B
        Primer: histopathology of calcineurin-inhibitor toxicity in renal allografts.
        Nat Clin Pract Nephrol. 2006; 2 (Available at:) (Accessed 12 June 2021): 398-404
        • Pochineni V
        • Rondon-Berrios H
        Electrolyte and acid-base disorders in the renal transplant recipient.
        Front Med (Lausanne). 2018; 5: 261
        • De Waele L
        • Van Gaal P
        • Abramowicz D
        Electrolytes disturbances after kidney transplantation.
        Acta Clin Belg. 2019; 74 (Available at:) (Accessed 12 June 2021): 48-52
        • Pihlstrom H
        • Dahle DO
        • Mjoen G
        • et al.
        Increased risk of all-cause mortality and renal graft loss in stable renal transplant recipients with hyperparathyroidism.
        Transplantation. 2015; 99 (Available at:) (Accessed 12 June 2021): 351-359
        • Bunnapradist S
        • Neri L
        • Wong W
        • et al.
        Incidence and risk factors for diarrhea following kidney transplantation and association with graft loss and mortality.
        Am J Kidney Dis. 2008; 51 (Available at:) (Accessed 12 June 2021): 478-486